The most important and recent new evidence for the effectiveness of MRB in TRH is the PATHWAY-2 study by Williams et al. [24••] published in the Lancet. In this randomized double-blind crossover trial, patients with hypertension resistant to 3 drugs including a diuretic were sequentially treated with spironolactone (n = 285), an α1 blocker doxazosin (n = 282), β blocker bisoprolol (n = 285) and a placebo (n = 274), each for 12 weeks, in random order, with 230 patients completing all treatment arms. This evidence concerns the gene TRH and Hypertension.